Download PDF
Semin Liver Dis 2006; 26(2): 087-096
DOI: 10.1055/s-2006-939754
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Hepatitis B Virus: Molecular Virology and Common Mutants

Tim J. Harrison1
  • 1Reader in Molecular Virology, UCL Institute of Hepatology, University College London, London, United Kingdom
Further Information

Publication History

Publication Date:
03 May 2006 (online)

    Permissions and Reprints

ABSTRACT

A high rate of viral turnover, combined with an error-prone polymerase, results in a very high frequency of mutational events during hepatitis B virus replication. Mutants may accumulate, particularly in individuals at advanced stages of persistent infection and with antibody- and cell-mediated immune responses to the virus. Specific mutants may be selected from these populations, especially by antibody and cytotoxic T lymphocyte responses and by antiviral therapy. In some cases, the mutants may be associated with especially severe acute hepatitis (including acute liver failure) and the development of sequelae such as cirrhosis and hepatocellular carcinoma. Antiviral resistance poses a challenge to therapy that might be overcome by the use of combinations of antiviral drugs.

KEYWORDS

Virus replication - reverse transcriptase - precore mutants - basic core promoter mutations - antibody escape - antiviral resistance

REFERENCES

  • 1 Norder H, Courouce A M, Coursaget P et al.. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.  Intervirology. 2004;  47 289-309
    CrossrefPubMedGoogle Scholar
  • 2 Kramvis A, Kew M, Francois G. Hepatitis B virus genotypes.  Vaccine. 2005;  23 2409-2423
    CrossrefPubMedGoogle Scholar
  • 3 Nowak M A, Bonhoeffer S, Hill A M, Boehme R, Thomas H C, McDade H. Viral dynamics in hepatitis B virus infection.  Proc Natl Acad Sci USA. 1996;  93 4398-4402
    CrossrefPubMedGoogle Scholar
  • 4 Harrison T J, Oon C J, Zuckerman A J. A novel antibody escape variant (ala 144) of hepatitis B virus in an identical twin before selection in the mother. In: Nishioka K, Suzuki H, Mishiro S, Oda T Viral Hepatitis and Liver Disease. Tokyo; Springer-Verlag 1994: 248-251
    Google Scholar
  • 5 Sen N, Cao F, Tavis J E. Translation of duck hepatitis B virus reverse transcriptase by ribosomal shunting.  J Virol. 2004;  78 11751-11757
    CrossrefPubMedGoogle Scholar
  • 6 Hadziyannis S J, Lieberman H M, Karvountzis G G, Shafritz D A. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus.  Hepatology. 1983;  3 656-662
    PubMedGoogle Scholar
  • 7 Carman W F, Jacyna M R, Hadziyannis S et al.. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.  Lancet. 1989;  2 588-591
    PubMedGoogle Scholar
  • 8 Brunetto M R, Stemler M, Bonino F et al.. A new hepatitis-B virus strain in patients with severe anti-Hbe positive chronic hepatitis-B.  J Hepatol. 1990;  10 258-261
    PubMedGoogle Scholar
  • 9 Okamoto H, Yotsumoto S, Akahane Y et al.. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen.  J Virol. 1990;  64 1298-1303
    PubMedGoogle Scholar
  • 10 Tong S P, Li J S, Vitvitski L, Trepo C. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region.  Virology. 1990;  176 596-603
    CrossrefPubMedGoogle Scholar
  • 11 Fiordalisi G, Cariani E, Mantero G et al.. High genomic variability in the pre-C region of hepatitis B virus in anti-HBe, HBV DNA-positive chronic hepatitis.  J Med Virol. 1990;  31 297-300
    PubMedGoogle Scholar
  • 12 Valliammai T, Thyagarajan S P, Zuckerman A J, Harrison T J. Precore and core mutations in HBV from individuals in India with chronic infection.  J Med Virol. 1995;  45 321-325
    PubMedGoogle Scholar
  • 13 Li J S, Tong S P, Wen Y M, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus genotype A rarely circulates as an HBe- minus mutant-possible contribution of a single nucleotide in the precore region.  J Virol. 1993;  67 5402-5410
    PubMedGoogle Scholar
  • 14 Aikawa T, Kanai K, Kako M et al.. Interferon-alpha 2a for chronic hepatitis B with e antigen or antibody: comparable antiviral effects on wild-type virus and precore mutant.  J Viral Hepat. 1995;  2 243-250
    PubMedGoogle Scholar
  • 15 Lampertico P, Delninno E, Manzin A et al.. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.  Hepatology. 1997;  26 1621-1625
    PubMedGoogle Scholar
  • 16 Okamoto H, Tsuda F, Akahane Y et al.. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen.  J Virol. 1994;  68 8102-8110
    PubMedGoogle Scholar
  • 17 Li J, Buckwold V E, Hon M W, Ou J H. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation.  J Virol. 1999;  73 1239-1244
    PubMedGoogle Scholar
  • 18 Takahashi K, Aoyama K, Ohno N et al.. The precore core promoter mutant (T(1762)A(1764)) of hepatitis B virus: clinical significance and an easy method for detection.  J Gen Virol. 1995;  76 3159-3164
    PubMedGoogle Scholar
  • 19 Hsia C C, Yuwen H, Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma.  Lancet. 1996;  348 625-626
    PubMedGoogle Scholar
  • 20 Fang Z L, Ling R, Wang S S, Nong J, Huang C S, Harrison T J. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China.  J Med Virol. 1998;  56 18-24
    CrossrefPubMedGoogle Scholar
  • 21 Fang Z L, Yang J Y, Ge X M et al.. Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China.  J Med Virol. 2002;  68 33-40
    CrossrefPubMedGoogle Scholar
  • 22 Kao J H, Chen P J, Lai M Y, Chen D S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.  Gastroenterology. 2003;  124 327-334
    CrossrefPubMedGoogle Scholar
  • 23 Gunther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H. Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease.  J Virol. 1996;  70 8318-8331
    PubMedGoogle Scholar
  • 24 Sendi H, Mehrab-Mohseni M, Zali M R, Norder H, Magnius L O. T-1764 G(1766) core promoter double mutants are restricted to hepatitis B virus strains with an A(1757) and are common in genotype D.  J Gen Virol. 2005;  86 2451-2458
    CrossrefPubMedGoogle Scholar
  • 25 Beath S V, Boxall E H, Watson R M, Tarlow M J, Kelly D A. Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers.  BMJ. 1992;  304 1169-1170
    PubMedGoogle Scholar
  • 26 Fagan E A, Smith P M, Davison F, Williams R. Fulminant hepatitis B in successive female sexual partners of two anti-HBe-positive males.  Lancet. 1986;  2 538-540
    PubMedGoogle Scholar
  • 27 Oren I, Hershow R C, Ben Porath E et al.. A common-source outbreak of fulminant hepatitis B in a hospital.  Ann Intern Med. 1989;  110 691-698
    PubMedGoogle Scholar
  • 28 Kojima M, Shimizu M, Tsuchimochi T et al.. Posttransfusion fulminant hepatitis B associated with precore-defective HBV mutants.  Vox Sang. 1991;  60 34-39
    PubMedGoogle Scholar
  • 29 Sato S, Suzuki K, Akahane Y et al.. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis.  Ann Intern Med. 1995;  122 241-248
    PubMedGoogle Scholar
  • 30 Liang T J, Hasegawa K, Rimon N, Wands J R, Ben Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis.  N Engl J Med. 1991;  324 1705-1709
    PubMedGoogle Scholar
  • 31 Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B.  Hepatology. 1999;  29 1252-1258
    CrossrefPubMedGoogle Scholar
  • 32 Sterneck M, Gunther S, Santantonio T et al.. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation.  Hepatology. 1996;  24 300-306
    PubMedGoogle Scholar
  • 33 Friedt M, Gerner P, Wintermeyer P, Wirth S. Complete hepatitis B virus genome analysis in HBsAg positive mothers and their infants with fulminant hepatitis B.  BMC Gastroenterol. 2004;  4 11
    CrossrefPubMedGoogle Scholar
  • 34 Takahashi K, Akahane Y, Gotanda T et al.. Demonstration of hepatitis B e antigen in the core of Dane particles.  J Immunol. 1979;  122 275-279
    PubMedGoogle Scholar
  • 35 Ehata T, Omata M, Yokosuka O, Hosoda K, Ohto M. Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis-B virus infection.  J Clin Invest. 1992;  89 332-338
    PubMedGoogle Scholar
  • 36 Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus.  Adv Virus Res. 1999;  52 25-137
    PubMedGoogle Scholar
  • 37 Suk F M, Lin M H, Newman M et al.. Replication advantage and host factor-independent phenotypes attributable to a common naturally occurring capsid mutation (197L) in human hepatitis B virus.  J Virol. 2002;  76 12069-12077
    CrossrefPubMedGoogle Scholar
  • 38 Le Pogam S, Yuan T T, Sahu G K, Chatterjee S, Shih C. Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein.  J Virol. 2000;  74 9099-9105
    CrossrefPubMedGoogle Scholar
  • 39 Rossner M T. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator.  J Med Virol. 1992;  36 101-117
    PubMedGoogle Scholar
  • 40 Bruss V, Lu X Y, Thomssen R, Gerlich W H. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein.  EMBO J. 1994;  13 2273-2279
    PubMedGoogle Scholar
  • 41 Lambert C, Mann S, Prange R. Assessment of determinants affecting the dual topology of hepadnaviral large envelope proteins.  J Gen Virol. 2004;  85 1221-1225
    CrossrefPubMedGoogle Scholar
  • 42 Neurath A R, Kent S B, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus.  Cell. 1986;  46 429-436
    CrossrefPubMedGoogle Scholar
  • 43 Chen Y CJ, Delbrook K, Dealwis C, Mimms L, Mushahwar I K, Mandecki W. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library.  Proc Natl Acad Sci U S A. 1996;  93 1997-2001
    CrossrefPubMedGoogle Scholar
  • 44 Okamoto H, Imai M, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr.  J Virol. 1987;  61 3030-3034
    PubMedGoogle Scholar
  • 45 Carman W F, Zanetti A R, Karayiannis P et al.. Vaccine-induced escape mutant of hepatitis B virus.  Lancet. 1990;  336 325-329
    CrossrefPubMedGoogle Scholar
  • 46 Oon C J, Lim G K, Ye Z et al.. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore.  Vaccine. 1995;  13 699-702
    CrossrefPubMedGoogle Scholar
  • 47 McMahon G, Ehrlich P H, Moustafa Z A et al.. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients.  Hepatology. 1992;  15 757-766
    PubMedGoogle Scholar
  • 48 Ghany M G, Ayola B, Villamil F G et al.. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.  Hepatology. 1998;  27 213-222
    CrossrefPubMedGoogle Scholar
  • 49 Protzer-Knolle U, Naumann U, Bartenschlager R et al.. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation.  Hepatology. 1998;  27 254-263
    CrossrefPubMedGoogle Scholar
  • 50 Fernholz D, Galle P R, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier.  Virology. 1993;  194 137-148
    CrossrefPubMedGoogle Scholar
  • 51 Summers J, Mason W S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate.  Cell. 1982;  29 403-415
    CrossrefPubMedGoogle Scholar
  • 52 Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus.  Nature. 1983;  305 827-829
    PubMedGoogle Scholar
  • 53 Stuyver L J, Locarnini S A, Lok A et al.. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.  Hepatology. 2001;  33 751-757
    CrossrefPubMedGoogle Scholar
  • 54 Lok A SF, Lai C L, Leung N et al.. Long-term safety of lamivudine treatment in patients with chronic hepatitis B.  Gastroenterology. 2003;  125 1714-1722
    CrossrefPubMedGoogle Scholar
  • 55 Ling R, Mutimer D, Ahmed N et al.. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.  Hepatology. 1996;  24 711-713
    PubMedGoogle Scholar
  • 56 Tipples G A, Ma M M, Fischer K P, Bain V G, Kneteman N M, Tyrrell D L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.  Hepatology. 1996;  24 714-717
    PubMedGoogle Scholar
  • 57 Buti M, Jardi R, Cotrina M, Rodriguezfrias F, Esteban R, Guardia J. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine.  J Hepatol. 1998;  28 510-513
    CrossrefPubMedGoogle Scholar
  • 58 Melegari M, Scaglioni P P, Wands J R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.  Hepatology. 1998;  27 628-633
    CrossrefPubMedGoogle Scholar
  • 59 Ling R, Harrison T J. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.  J Gen Virol. 1999;  80 601-606
    PubMedGoogle Scholar
  • 60 Niesters H GM, Deman R A, Pas S D, Fries E, Osterhaus ADME. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy.  J Med Microbiol. 2002;  51 695-699
    PubMedGoogle Scholar
  • 61 Bozdayi A M, Uzunalimoglu O, Turkyilmaz A R et al.. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.  J Viral Hepat. 2003;  10 256-265
    CrossrefPubMedGoogle Scholar
  • 62 Perrillo R, Schiff E, Yoshida E et al.. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.  Hepatology. 2000;  32 129-134
    CrossrefPubMedGoogle Scholar
  • 63 Fung S K, Chae H B, Fontana R J et al.. Virologic response and resistance to adefovir in patients with chronic hepatitis B.  J Hepatol. 2006;  44 283-290
    CrossrefPubMedGoogle Scholar
  • 64 Angus P, Vaughan R, Xiong S et al.. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.  Gastroenterology. 2003;  125 292-297
    CrossrefPubMedGoogle Scholar
  • 65 Villeneuve J P, Durantel D, Durantel S et al.. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.  J Hepatol. 2003;  39 1085-1089
    CrossrefPubMedGoogle Scholar
  • 66 Zoulim F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models.  J Antimicrob Chemother. 2005;  55 608-611
    CrossrefPubMedGoogle Scholar
  • 67 Seifer M, Hamatake R K, Colonno R J, Standring D N. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.  Antimicrob Agents Chemother. 1998;  42 3200-3208
    PubMedGoogle Scholar
  • 68 Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection.  Curr Med Res Opin. 2005;  21 1845-1856
    CrossrefPubMedGoogle Scholar
  • 69 Torresi J, Earnest-Silveira L, Deliyannis G et al.. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.  Virology. 2002;  293 305-313
    CrossrefPubMedGoogle Scholar
  • 70 Torresi J, Earnest-Silveira L, Civitico G et al.. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.  Virology. 2002;  299 88-99
    CrossrefPubMedGoogle Scholar

Tim J HarrisonPh.D. D.Sc. F.R.C.Path. 

Reader in Molecular Virology, UCL Institute of Hepatology, University College London

Windeyer Building, 46 Cleveland Street, London W1T 4JF, United Kingdom

      >